• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Arabian Journal for Science and Engineering >Artificial Pancreas Coupled Vital Signs Monitoring for Improved Patient Safety
【24h】

Artificial Pancreas Coupled Vital Signs Monitoring for Improved Patient Safety

机译：人工胰腺耦合生命体征监测可提高患者安全性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This paper describes an improved design of artificial pancreas, which takes into account the physical parameters of human body for detecting hypoglycemic state of diabetic patients. In diabetes mellitus, failure in endogenous insulin production requires exogenous infusion of required drug amount. Traditionally, a closed-loop blood glucose level (BGL) control system includes a patient, continuous glucose monitor, controller and an insulin pump as the actuating device. Such systems are not perfectly safe to use as an overdose due to late action of insulin and/or delay in reading sensor data may lead to dangerously low blood sugar levels (hypoglycemia). Our design incorporates vital signs such as electrocardiogram, heart beat rate, electroencephalogra-phy and skin resistance for early detection and avoidance of hypoglycemia state. The objective is to securely control BGL of a patient suffering from diabetes and to prevent the harmful state of hypoglycemia. A typical proportional integrate derivative controller is designed for keeping glucose level inside the desired 'safe' range under normal conditions. Once hypoglycemia is detected, a specified amount of glucagon is infused into the patient's body. The simulations have shown that patient safety can be improved through this strategy.In addition, the model-based design of the purposed system is validated by the UPPAAL model checker tool.
机译：本文介绍了一种人工胰腺的改进设计，该模型考虑了人体的物理参数以检测糖尿病患者的低血糖状态。在糖尿病中，内源性胰岛素产生失败需要外源输注所需药物量。传统上，闭环血糖水平（BGL）控制系统包括患者，连续血糖监测仪，控制器和胰岛素泵作为驱动装置。由于胰岛素的晚期作用和/或读取传感器数据的延迟可能导致危险的低血糖水平（低血糖症），因此此类系统不能完全安全地用作过量用药。我们的设计结合了生命体征，例如心电图，心跳率，脑电图和皮肤阻力，可尽早发现并避免出现低血糖状态。目的是安全地控制患有糖尿病的患者的BGL并预防低血糖症的有害状态。典型的比例积分微分控制器设计用于在正常条件下将葡萄糖水平保持在所需的“安全”范围内。一旦检测到低血糖，就将特定量的胰高血糖素注入患者体内。仿真表明，通过这种策略可以提高患者的安全性。此外，通过UPPAAL模型检查器工具对目标系统的基于模型的设计进行了验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号